Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer

Authors

Dave S B Hoon, Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA 90404 USA.Follow
Laurent Lessard

Document Type

Patent

Publication Date

11-30-2012

Abstract

Long noncoding RNAs (lncRNAs) that may be used as cancer biomarkers and methods of diagnosing, prognosing and monitoring cancer including, but not limited to, cutaneous melanoma using said lncRNAs are provided herein. In some embodiments, the methods include steps of isolating one or more lncRNA transcripts in a biological sample from the subject; measuring a test level of the one or more isolated lncRNA transcripts; comparing the test level to a control level of the one or more lncRNA transcripts; and diagnosing or making a prognosis based on the lncRNA level. In some embodiments, the lncRNA transcript is an linc00340 transcript or variant thereof. These lncRNA transcripts may also be used as a therapeutic target in the treatment of cancer.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Location

United States

Comments

Patent Number: 9,410,206

Assignee

JOHN WAYNE CANCER INSTITUTE (Santa Monica, CA)

Family ID

48744326

Serial Number

13/691,716

Tech ID

11-JWCI-067